5 research outputs found
Synthesis, Biological Evaluation and Docking Studies of Ring-Opened Analogues of Ipomoeassin F
The plant-derived macrocyclic resin glycoside ipomoeassin F (Ipom-F) binds to Sec61α
and significantly disrupts multiple aspects of Sec61-mediated protein biogenesis at the endoplas mic reticulum, ultimately leading to cell death. However, extensive assessment of Ipom-F as a
molecular tool and a therapeutic lead is hampered by its limited production scale, largely caused
by intramolecular assembly of the macrocyclic ring. Here, using in vitro and/or in cellula biological
assays to explore the first series of ring-opened analogues for the ipomoeassins, and indeed all resin
glycosides, we provide clear evidence that macrocyclic integrity is not required for the cytotoxic
inhibition of Sec61-dependent protein translocation by Ipom-F. Furthermore, our modeling suggests
that open-chain analogues of Ipom-F can interact with multiple sites on the Sec61α subunit, most
likely located at a previously identified binding site for mycolactone and/or the so-called lateral gate.
Subsequent in silico-aided design led to the discovery of the stereochemically simplified analogue 3
as a potent, alternative lead compound that could be synthesized much more efficiently than Ipom-F
and will accelerate future ipomoeassin research in chemical biology and drug discovery. Our work
may also inspire further exploration of ring-opened analogues of other resin glycosides
Synthesis, Biological Evaluation and Docking Studies of Ring-Opened Analogues of Ipomoeassin F
The plant-derived macrocyclic resin glycoside ipomoeassin F (Ipom-F) binds to Sec61α and significantly disrupts multiple aspects of Sec61-mediated protein biogenesis at the endoplasmic reticulum, ultimately leading to cell death. However, extensive assessment of Ipom-F as a molecular tool and a therapeutic lead is hampered by its limited production scale, largely caused by intramolecular assembly of the macrocyclic ring. Here, using in vitro and/or in cellula biological assays to explore the first series of ring-opened analogues for the ipomoeassins, and indeed all resin glycosides, we provide clear evidence that macrocyclic integrity is not required for the cytotoxic inhibition of Sec61-dependent protein translocation by Ipom-F. Furthermore, our modeling suggests that open-chain analogues of Ipom-F can interact with multiple sites on the Sec61α subunit, most likely located at a previously identified binding site for mycolactone and/or the so-called lateral gate. Subsequent in silico-aided design led to the discovery of the stereochemically simplified analogue 3 as a potent, alternative lead compound that could be synthesized much more efficiently than Ipom-F and will accelerate future ipomoeassin research in chemical biology and drug discovery. Our work may also inspire further exploration of ring-opened analogues of other resin glycosides
Biology-directed and in silico-aided design liberates a potent, simplified and ipomoeassin-F-derived Sec61 inhibitor
The macrocyclic small molecule inhibitor ipomoeassin F (Ipom-F) binds to the central Sec61α subunit of the Sec61 complex and induces cytotoxicity by disrupting multiple aspects of Sec61-mediated protein biogenesis at the endoplasmic reticulum (ER). Here, we show that the integrity of the Ipom-F macrocycle is not required either for
Sec61 inhibition in vitro or the induction of cell death, which is abrogated in cells expressing a resistance-conferring Sec61α mutant. We conclude that Ipom-F and its open-chain analogues interact with Sec61α via its mycolactone binding site and/or lateral gate, thereby occluding the normal Sec61-mediated pathway for membrane protein insertion at the ER. Using biology-directed and in silico-aided design, we have revolutionised the production of Ipom-F to yield open-chain analogue 3; a potent, simplified and synthetically accessible Ipom-F-derived Sec61 inhibitor. We present 3 as a lead compound for the generation of new protein translocation probes and future therapeutic development
Synthesis, Biological Evaluation and Docking Studies of Ring-Opened Analogues of Ipomoeassin F
The plant-derived macrocyclic resin glycoside ipomoeassin F (Ipom-F) binds to Sec61α and significantly disrupts multiple aspects of Sec61-mediated protein biogenesis at the endoplasmic reticulum, ultimately leading to cell death. However, extensive assessment of Ipom-F as a molecular tool and a therapeutic lead is hampered by its limited production scale, largely caused by intramolecular assembly of the macrocyclic ring. Here, using in vitro and/or in cellula biological assays to explore the first series of ring-opened analogues for the ipomoeassins, and indeed all resin glycosides, we provide clear evidence that macrocyclic integrity is not required for the cytotoxic inhibition of Sec61-dependent protein translocation by Ipom-F. Furthermore, our modeling suggests that open-chain analogues of Ipom-F can interact with multiple sites on the Sec61α subunit, most likely located at a previously identified binding site for mycolactone and/or the so-called lateral gate. Subsequent in silico-aided design led to the discovery of the stereochemically simplified analogue 3 as a potent, alternative lead compound that could be synthesized much more efficiently than Ipom-F and will accelerate future ipomoeassin research in chemical biology and drug discovery. Our work may also inspire further exploration of ring-opened analogues of other resin glycosides